FINWIRES · TerminalLIVE
FINWIRES

Piper Sandler Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $25 From $2

By

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $31.78, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles